Thiogenesis Therapeutics (TSXV:TTI) Capital Expenditure : C$0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Thiogenesis Therapeutics's cash flow for capital expenditures for the three months ended in Mar. 2025 was C$0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was C$0.00 Mil.

Thiogenesis Therapeutics Capital Expenditure Historical Data

The historical data trend for Thiogenesis Therapeutics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Capital Expenditure Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Dec24

Capital Expenditure

Get a 7-Day Free Trial

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capital Expenditure	Get a 7-Day Free Trial													-	-	-	-	-

Thiogenesis Therapeutics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives